OBI Pharma Updates on Clinical Trial Activities During COVID-19 Pandemic

TAIPEI, TAIWAN. APRIL 8, 2020– OBI Pharma has been closely monitoring the impact of the COVID-19 pandemic worldwide. We realize the intense challenges that patients and our clinical research investigators and institutions are under due to the COVID-19 crisis. Therefore, in order to allow our collaborating clinical research centers to prioritize response to the pandemic, […]

HOMEWhat’s NewNewsOBI Pharma Updates on Clinical Trial Activities During COVID-19 Pandemic

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2020.Jan.21

OBI Pharma Granted U.S. FDA Orphan Drug Designation for the Treatment of Gastric Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999

2020.May.20

OBI Pharma Announces Poster Presentations at 2020 ASCO Virtual Annual Meeting for Adagloxad Simolenin, OBI-999 and OBI-3424